• Immutep released first survival results from its Phase II EFTISARC-NEO trial, showing encouraging preliminary outcomes in patients with resectable soft tissue sarcoma.
• The trial evaluates eftilagimod alfa with Keytruda and radiotherapy before surgery; it previously met its primary endpoint.
• Investigators concluded the survival findings warrant trials aimed at supporting registration; follow-up remains ongoing.
• Results appeared in a CTOS 2026 abstract; updated analyses will be presented Nov. 19, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.